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A B S T R A C T
Benign and malignant neoplasms of the temporomandibular joint are uncommon. Their presence poses
a diagnostic and therapeutic challenge for clinicians. The central giant cell granuloma is a relatively common
lesion of the jaws; however, it has been reported rarely to originate from the mandibular condyle. To date,
only 5 such cases have been documented. We report a case of a large central giant cell granuloma of the
condylar head with extension into the infratemporal fossa in a 29-year-old male. The patient was treated
with resection and reconstruction using a costochondral graft. The signs, symptoms, and radiographic
features are described and compared with the previous reports in the literature. The therapeutic options
detailed in the literature have been focused mainly on lesions occupying the dentate regions of the maxilla
and mandible. As such, we will review the surgical and pharmacologic options available to the surgeon
and discuss their appropriateness with regard to this unique presentation of the central giant cell granuloma.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Neoplasms of the temporomandibular joint (TMJ) are uncom-
mon and often confused in the early stages for the more common
TMJ dysfunction or derangement [1]. The presence of a central giant
cell granuloma (CGCG) in the mandibular condyle has been re-
ported rarely. The purpose of this study is to provide clinicians with
a description of the clinical features of a CGCG presenting in the
mandibular condyle as well as an analysis of the literature and dis-
cussion of the therapeutic strategies available and appropriate for
this unique location.
2. Presentation of case
A 29-year-old healthy Caucasian male with a history of a pain-
less left preauricular mass of 6 months’ duration was referred by
his dentist to the Department of Oral and Maxillofacial Surgery at
the Montreal General Hospital for evaluation (Figure 1). A pan-
oramic radiograph taken by the patient’s dentist demonstrated a
large radiolucent mass of the left condylar process (Figure 2).
The patient noted a progressive enlargement of the mass since
its onset and in the days preceding the consultation a new ﬁnding
of hypoesthesia over the distribution of the mandibular division
of the trigeminal nerve while sleeping on his left side. The patient
reported no changes in his occlusion but some resistance and
mild discomfort on maximal opening. On physical examination,
the patient was found to have a ﬁrm, nontender, palpable mass in
the left preauricular region. Clicking or crepitus of the TMJs bilat-
erally was absent. The maximal mouth opening, left and right
lateral excursive movements were found to be 38 mm, 5 mm, and
5 mm, respectively. There was no deviation of the mandible on
opening or closing movements. Trigeminal nerve function was
normal when no pressure was applied to the left preauricular
region. With prolonged pressure to the left preauricular area, the
patient reported hypoesthesia over the distribution of the man-
dibular nerve.
The computed tomography scan of the facial bones demon-
strated a 5.5 × 3.8 × 3.4-cm radiolucentmass emanating from the left
condylar head (Figure 3). The condylewas displaced inferiorly in the
fossa toaccommodate themass. Theoutlinedemonstrateda thincortex
with a few breaks at the periphery. There were no signs of invasion
of the surrounding soft tissues. The radiographic appearanceof awell-
deﬁned, corticated mass without soft tissue invasion or skull base
resorption was suggestive of a benign aggressive tumor.
An open biopsy of the left condylar mass was performed under
general anesthesia. An intraoperative frozen section analysis favored
* Corresponding author. Department of Oral and Maxillofacial Surgery, Faculty of
Dentistry, McGill University Health Centre, 1650 Cedar Ave, Room B3-119.1, Mon-
treal, Québec H3G 1A4, Canada. Tel.: +1-514-934-1934 ext: 42468; fax: +1-514-
934-8340.
E-mail address: jordan.gigliotti@mail.mcgill.ca (J. Gigliotti).
Oral and Maxillofacial Surgery Cases 1 (2015) 42–46
Contents lists available at ScienceDirect
Oral and Maxillofacial Surgery Cases
journal homepage: www.oralandmaxi l lofac ia lsurgerycases.com
2214-5419 © 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.omsc.2015.08.001
a benign entity but was inconclusive. The ﬁnal pathology was con-
sistent with a CGCG (Figure 4). Intact parathyroid hormone
(4.00 pmol/L) and total calcium (2.42 mmol/L) studies were deter-
mined to be within normal limits, ruling out a brown tumor of
hyperparathyroidism.
A decisionwasmade to resect the condylarmass and reconstruct
the defectwith a costochondral graft under general anesthesia. Given
the extension of the tumor into the ramus of the mandible, infra-
temporal fossa, and medially toward the pterygoid plates, 2 inci-
sions were employed for resection: a preauricular and a trans-oral
incision. First, a modiﬁed preauricular incision [2] was completed,
withdissectiondownto the lateral aspectof the tumor.Once the latero-
anterior and posterior aspectswere exposed, the left zygomatic arch
waspre-plated thenosteotomized to facilitate access for superior dis-
section into the infratemporal fossa. Access to the medial aspect of
the tumor was facilitated by a trans-oral mandibular vestibule inci-
sion, allowing for gentle dissection up to the pterygoid plates. Once
circumferential dissectionwas complete, the inferiormandibular re-
section margin was osteotomized, thus allowing for delivery of the
tumor in an inferolateral direction in one segmentwith the articular
disc attached (Figure 5). Access through the trans-oral and preau-
ricular sites facilitatedcompleteandsafedissectionof the tumor,while
a submandibular incisionwas used to allow access and placement of
the costochondral graft into the proper anatomic site.
The ﬁnal histopathologic diagnosis was a CGCG with some areas
of aneurysmal bone cyst-like features. At the 12-month follow-up ap-
pointment, the patient’s maximal mouth opening and left and right
lateralexcursivemovementshad increasedto45mm,8mm,and8mm,
respectively, while his preoperative occlusion remained intact.
3. Discussion
To date, 5 cases of CGCGs centering on the mandibular condyle
have been published in the English literature (Table 1) [3–7].
Figure 1. Frontal photograph showing a left preauricular mass.
Table 1
Comparison of published cases of CGCGs originating in the mandibular condyle.
Shensa and
Nasseri [3]
Tasanen et al. [4] Abu-El-Naaj et al. [5] Jadu et al. [6] Munzenmayer
et al. [7]
Current study
Age at
presentation
15 59 15 31 19 29
Gender Male Male Female Male Female Male
Clinical
ﬁndings
Expansile mass Firm, preauricular
swelling; 20-mm
mouth opening with
deviation to
ipsilateral side
Preauricular swelling;
no restriction in
mandibular
movements or
occlusal changes
Firm, nodular,
preauricular swelling
Examination was
normal; incidental
radiographic ﬁnding
Firm, nodular, preauricular
swelling; nontender;
no change in occlusion
Imaging
features
Well-deﬁned
radiolucency
Well-deﬁned,
multilocular
radiolucency
3 × 2-cm well-deﬁned
unilocular
radiolucency with
cortical expansion
Well-deﬁned,
multilocular
radiolucency with
granular bone
pattern
Well-deﬁned,
multilocular
radiolucency with
granular bone
pattern
Thinly corticated,
5.5 × 3.8 × 3.4-cm
multilocular mass
Symptoms Asymptomatic Noted painless, slow
growing preauricular
lump
Asymptomatic Dull aching pain and
progressive
limitation in mouth
opening over 2 y
Asymptomatic Mild discomfort and
resistance on maximal
opening; mandibular
nerve hypoesthesia
when sleeping on
ipsilateral side
Management Enucleation Resection and
reconstruction with
costochondral graft
Enucleation Enucleation Resection and
reconstruction with
nonvascularized
ﬁbula graft
Resection and
reconstruction with
costochondral graft
Outcome N/A No evidence of
recurrence at 21 mo
No evidence of
recurrence at 6 mo
Recurrence requiring
resection and
alloplastic total joint
replacement
No evidence of
recurrence at 24 mo
No evidence of recurrence
at 6 mo
N/A, not applicable.
Figure 2. Panoramic radiograph displaying a thinly corticated radiolucent lesion of
the left mandibular condyle.
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Including our case report, there is a 2:1 (M-F) gender predilection.
This is in contrast tomost previous publications that indicate a female
tendency. The mean age at presentation is 28 years of age (range
15-59). Of the 6 patients, 4 were asymptomatic on presentation. The
remaining 2 patients experienced mild discomfort presumably
related to the mass effect of the tumor and not inherent to the neo-
plasm itself. Three patients presented with a mild restriction in
mouth opening and all patients reported no changes in occlusion.
Clinically, 5 of the 6 patients developed ﬁrm preauricular swell-
ings. Radiographically, the lesions were predominately multilocu-
lar in nature and surrounded by a well-deﬁned cortical layer.
The management of the CGCG is controversial. Multiple medical
management strategies have been proposed over time with varying
degrees of success despite not necessarily targeting the now pro-
posed proliferative cell (spindle-shaped mononuclear stromal cell)
[8]. A 2009 Cochrane Review concluded that there was only 1 ran-
domized controlled trial available and no high-quality evidence to
support the use of nonsurgical therapies in the management of
CGCGs [9].
Surgical management of the CGCG is still themost common treat-
ment modality employed. Broadly, it can be broken into 2 major in-
terventions: curettage ± adjunctive treatments (eg cryotherapy,
peripheral ostectomy) and resection.With curettage recurrence rates
from 11% to 49% [10,11] have been reported. A study by de Lange
and Van den Akker [12] followed up 80 patients after curettage. Pa-
tients with aggressive lesions had a recurrence rate of 37.5% while
Figure 3. CT scan, soft tissue window, demonstrating a 5.5 × 3.8 × 3.4-cm radiolucent mass of the left mandibular condyle in the (A) axial (B) coronal, and (C) sagittal planes.
Figure 4. H&E stained photomicrographs (A) 50× and (B) 400× showing a cellular matrix predominantly of oval and spindle-shaped stromal cells interspersed with mul-
tinucleated giant cells. There is extensive extravasation of red blood cells and hemosiderin deposition (B).
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patients classiﬁed as having nonaggressive lesions had a recur-
rence rate of 23.4%. Bataineh et al. [13] evaluated the effectiveness
of resectionwith a 1-cmmargin in 18 patients with aggressive CGCGs
of the mandible. During the follow-up period only one patient re-
curred (6.8%). Disease control is superior with resection; however,
it is also more frequently associated with tooth loss, damage to de-
veloping tooth germs, neurosensory disturbances, fracture, and the
use of general anesthesia.
In 1988, Jacoway et al. [14] described a protocol that involved
intralesional injection of equal parts of triamcinolone hexacetonide
and 0.5% bupivacaine (1:200,000 epinephrine). Ten milliliters of so-
lution was injected per 1 cm of lesion, as determined on Panorex
imaging, weekly over a period of 6 weeks. The original rationale for
this therapy was the histologic resemblance of the CGCG to sarcoid
lesions, which were known to respond to steroids [15]. The largest
case series to date was published by Nogueira et al. [16]. Of the 21
patients in the study, 15 showed a good response, 4 demonstrated
a moderate response, and 2 patients had a negative response. Fur-
thermore, 8 of 19 patients with a moderate-to-good response (in-
creased radiopacity) still required an osteoplasty to reestablish facial
aesthetics.
Harris [17] was the ﬁrst to propose the use of subcutaneous
human calcitonin for the treatment of CGCGs. Due to its commer-
cial availability, salmon calcitonin is now used either subcutane-
ously or intranasally. In 2003, Pogrel [15] published a series of 10
cases. Nine patients received daily subcutaneous injections while
1 patient elected for the intranasal route of administration. In all
cases, there were no radiographic changes at 4-6months, but there-
after calciﬁcation appeared quickly up to 18 months. Of the 9 pa-
tients receiving subcutaneous injections one recurred after 26
months and was curettage was performed, while the patient re-
ceiving the intranasal calcitonin abandoned the treatment after 4
months and curettage was performed as well. Treatment dura-
tions ranged from 19 to 26 months in the 7 patients free of recur-
rence. Similarly to corticosteroid treatment, the use of calcitonin
may result in an increase in radiopacity and histologic resolution
of the lesion, but may not necessarily restore the normal bony ar-
chitecture of the jaw.
Kaban et al. [18] were the ﬁrst to describe the successful use of
interferon alfa-2a in the treatment of an aggressive CGCG. Among
its other effects, interferon alfa-2a is a known inhibitor of basic ﬁ-
broblast growth factor. At this time, proliferative vascular lesions,
namely, the hemangioma, known to overexpress basic ﬁbroblast
growth factor, had been treated successfully with interferon alfa-
2a. It is now appreciated that the CGCG likely does not represent a
proliferative vascular lesion; however, the angiogenic factors may
play a role in the osteoclastogenesis and thus in the growth of the
lesion. Kaban et al. [19] further demonstrated the eﬃcacy of inter-
feron alfa-2a in a retrospective case series of 16 patients with ag-
gressive CGCGs. All patients were initially treated with curettage
followed by interferon therapy for a mean duration of 7 months. No
tumor recurrence was seen in this population after at least 2 years
of therapy. In this series 88.5% of patients developed 1 or more side
effects, 42.3% required their dose to be reduced as a result, and 15.3%
developed side effects necessitating cessation of treatment. The role
of interferon alfa-2a as a monotherapy is less certain as it does not
target the suspected proliferative spindle-shaped stromal cell.
When managing neoplasms of the mandibular condyle, non-
surgical management with preservation of the native condyle is
highly desirable. Unfortunately, there is no medical management
strategy that appears to be effective in every individual patient with
a CGCG. Based on the literature, condylar resection with immedi-
ate reconstruction has the lowest recurrence rate with the short-
est duration of treatment. Interferon alfa-2a therapy has
demonstrated the best results when used as adjuvant therapy fol-
lowing curettage. The morbidity associated with curettage of a large
condylar lesion and resection is similar. As such, this treatment strat-
egy offers little advantage over resection, given the disadvantages
of prolonged treatment duration and high incidence of side effects.
Intralesional corticosteroid treatment requires multiple injections
over a period of at least 6 weeks [14]. Repeated injections in the
TMJ and infratemporal fossa regions are not without risk of neu-
rovascular injury possibly resulting in paresthesia, paresis, hema-
toma, or pseudoaneurysm formation. Additionally, the administration
of solution into the deep aspect of the lesion would be challeng-
ing, possibly compromising the outcome. The administration of sub-
cutaneous calcitonin-like corticosteroids has had some success but
requires daily subcutaneous injection and an extended treatment
duration often spanning over 2 years [15]. Unfortunately, the in-
tranasal form has demonstrated limited success thus far [20]. The
side effects of calcitonin are usually minimal but can include nausea,
ﬂushing, and dizziness [20]. In medical treatment of large lesions,
the normal anatomic form is often not achieved [15,16] and further
osteoplasty is often required for a desirable cosmetic result. Achiev-
ing a normal anatomic form of the TMJ is of paramount impor-
tance, further complicating medical management strategies. A goal
less than this will result in residual facial deformity and persis-
tence of preoperative symptoms that may include limitation in
mouth opening, pain, and neurosensory disturbances. Based on the
available literature, it was determined that condylar resection with
immediate reconstruction would be the most appropriate treat-
ment for a large, aggressive, symptomatic, and deforming CGCG of
the mandibular condyle in the adult patient. The role of nonsurgi-
cal therapies may be increasingly important when condylar CGCGs
are asymptomatic, small, and classiﬁed as nonaggressive in the
growing individual.
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